The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Learnings from a multiphase, mixed-methods lung cancer quality initiative in U.S. community cancer centers.
 
Matthew Smeltzer
Other Relationship - Association of Community Cancer Centers (ACCC)
 
Percy Lee
Honoraria - AstraZeneca/MedImmune; Varian Medical Systems; ViewRay
Consulting or Advisory Role - Varian Medical Systems; ViewRay
Speakers' Bureau - AstraZeneca/MedImmune
Research Funding - AstraZeneca/MedImmune; AstraZeneca/MedImmune
Travel, Accommodations, Expenses - AstraZeneca/MedImmune; Varian Medical Systems; ViewRay; ViewRay
 
Joseph Kim
No Relationships to Disclose
 
David R. Spigel
Leadership - ASCO (Inst)
Consulting or Advisory Role - Amgen (Inst); Aptitude Health (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Curio Science (Inst); Dracen (Inst); EMD Serono (Inst); Evelo Therapeutics (Inst); Exelixis (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Iksuda Therapeutics (Inst); Illumina (Inst); Intellisphere (Inst); Ipsen (Inst); Jazz Pharmaceuticals (Inst); Merck (Inst); Mirati Therapeutics (Inst); Molecular Templates (Inst); Nektar (Inst); Novartis (Inst); Novocure (Inst); Pfizer (Inst); PharmaMar (Inst); Puma Biotechnology (Inst); Regeneron (Inst); Sanofi/Aventis (Inst); Seagen (Inst); Takeda (Inst); TRIPTYCH Health Partners (Inst); TRM Oncology (Inst)
Research Funding - Aeglea Biotherapeutics (Inst); Agios (Inst); Apollomics (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); BIND Therapeutics (Inst); Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Celgene (Inst); Celldex (Inst); Clovis Oncology (Inst); cyteir (Inst); Daiichi Sankyo (Inst); Eisai (Inst); Elevation Oncology (Inst); EMD Serono (Inst); G1 Therapeutics (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); GRAIL (Inst); ImClone Systems (Inst); Immunogen (Inst); Ipsen (Inst); Janssen Oncology (Inst); Lilly (Inst); MedImmune (Inst); Merck (Inst); Molecular Partners (Inst); Nektar (Inst); Neon Therapeutics (Inst); Novartis (Inst); Novocure (Inst); Takeda (Inst); Tesaro (Inst); Transgene (Inst); University of Texas Southwestern Medical Center - Simmons Cancer Center (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Genentech; Novartis
 
Brendon Matthew Stiles
Employment - PPD (I); Xalud Therapeutics (I); Xalud Therapeutics (I)
Leadership - PPD (I); Verrica Pharmaceuticals (I)
Stock and Other Ownership Interests - Pfizer (I); PPD (I); Xalud Therapeutics (I)
Honoraria - AstraZeneca; Bristol Myers Squibb; Genentech; Pfizer
Consulting or Advisory Role - AstraZeneca; Gala Therapeutics; Pfizer
Other Relationship - Lung Cancer Research Foundation
 
Alexander I. Spira
Stock and Other Ownership Interests - Lilly
Honoraria - Amgen; AstraZeneca/MedImmune; Bayer; Bristol-Myers Squibb; CytomX Therapeutics; Janssen Oncology; Merck; Novartis; Takeda
Consulting or Advisory Role - Amgen; Array BioPharma (Inst); AstraZeneca/MedImmune (Inst); AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); Gritstone Bio; incyte; Jazz Pharmaceuticals; Merck (Inst); Mirati Therapeutics; Novartis
Research Funding - Abbvie (Inst); ADC Therapeutics (Inst); ADC Therapeutics (Inst); Amgen (Inst); Arch Therapeutics (Inst); Astellas Pharma (Inst); Astex Pharmaceuticals (Inst); AstraZeneca (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); CytomX Therapeutics (Inst); Daiichi Sankyo (Inst); Gritstone Bio (Inst); Ignyta (Inst); Incyte (Inst); Janssen Oncology (Inst); LAM Therapeutics; LAM Therapeutics (Inst); Loxo (Inst); Loxo (Inst); Macrogenics (Inst); MedImmune (Inst); Mirati Therapeutics (Inst); Newlink Genetics (Inst); Novartis (Inst); Plexxikon (Inst); Roche (Inst); Rubius Therapeutics (Inst); Takeda (Inst); Trovagene (Inst)
 
Ravi Salgia
Consulting or Advisory Role - Abbvie; AstraZeneca; Iovance Biotherapeutics; Novartis
Speakers' Bureau - AstraZeneca; Merck
 
Howard West
Honoraria - AstraZeneca; Genentech/Roche; Merck; Mirati Therapeutics; Regeneron; Takeda
Consulting or Advisory Role - AstraZeneca; Genentech/Roche; Merck; Mirati Therapeutics; Regeneron; Regeneron; Takeda
Speakers' Bureau - AstraZeneca; Merck; Takeda
 
Michelle Shiller
No Relationships to Disclose
 
Elana Plotkin
No Relationships to Disclose
 
Lorna Lucas
No Relationships to Disclose
 
Leigh Boehmer
Consulting or Advisory Role - Pfizer